安濟盛(sheng)生物醫(yi)藥(yao)技(ji)術(廣州)有限公(gong)司成立于(yu)2018年6月,是一家專注于(yu)骨骼、肌肉和關節疾病(bing)全新(xin)藥(yao)物研發的創業企業。公(gong)司主要(yao)創始人(ren)曾于(yu)多(duo)家國際知名(ming)(ming)(ming)藥(yao)企擔任(ren)藥(yao)物研發和重(zhong)要(yao)管理職務,核心成員在過(guo)去二十多(duo)年中(zhong)曾帶領不同公(gong)司團隊為多(duo)個重(zhong)要(yao)骨疾病(bing)上市(shi)藥(yao)物的研究(jiu)和臨床開發作出重(zhong)大貢獻,包括denosumab (商品名(ming)(ming)(ming):Prolia和Xgeva)、romosozumab (商品名(ming)(ming)(ming):Evenity)、 拉索昔芬(fen)lasofoxifene(商品名(ming)(ming)(ming):Fablyn)、Raloxifene (商品名(ming)(ming)(ming):Evista) 以及Teriparatide (商品名(ming)(ming)(ming):Forteo) 。